Cyclacel Pharmaceuticals, Inc.
CYCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -42.73 | 0.02 | -0.00 | 1.00 |
| FCF Yield | 45.50% | -0.01% | -0.37% | -0.17% |
| EV / EBITDA | -9,646.46 | -2.72 | 0.51 | -413.14 |
| Quality | ||||
| ROIC | -13.86% | -36,226.35% | -163.99% | 138.06% |
| Gross Margin | 20.99% | 0.00% | 0.00% | 111.43% |
| Cash Conversion Ratio | 3.08 | 0.80 | 40.09 | 0.44 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | 199,900.00% |
| Free Cash Flow Growth | 407,132.48% | 67.48% | 99.76% | 55.79% |
| Safety | ||||
| Net Debt / EBITDA | 3.92 | 3.24 | 0.68 | 1.66 |
| Interest Coverage | -110.22 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.05 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2,071.18 | -19,890.00 | 0.00 | -104,086.93 |